This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug
by Zacks Equity Research
Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Nuveen ESG Large-Cap Value ETF (NULV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NULV
Sanofi (SNY) Moves 6.0% Higher: Will This Strength Last?
by Zacks Equity Research
Sanofi (SNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Add Novo (NVO) Stock to Your Portfolio
by Zacks Equity Research
Novo (NVO), a top-ranked stock at present, enjoys a strong foothold in the Diabetes Care market with increasing market shares driven by Rybelsus, Ozempic and Victoza's strong performance.
The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton
by Zacks Equity Research
Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton are part of the Zacks top Analyst Blog.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $105.54, marking a -0.29% move from the previous day.
Top Research Reports for Merck, Intel & MercadoLibre
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Intel Corporation (INTC) and MercadoLibre, Inc. (MELI).
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study
by Zacks Equity Research
Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.
Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote
by Zacks Equity Research
FDA's Antimicrobial Drugs Advisory Committee (AMDAC) votes 16 to 1 for Pfizer's Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients at high risk of hospitalization or death.
Pharma Stock Roundup: M&A Boom in Drug Industry With PFE & SNY Deals, Other Updates
by Kinjel Shah
Pfizer (PFE) is set to buy Seagen (SGEN) for $43 billion while Sanofi (SNY) is acquiring Provention Bio. Novo Nordisk (NVO) and Sanofi are looking to cut insulin prices.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $107.63, marking a +0.62% move from the previous day.
AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?
by Zacks Equity Research
AstraZeneca (AZN) expects total revenues to increase in the low-to-mid single-digit percentage in 2023 at CER.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Pfizer (PFE) to Buy Seagen for $43B, Boost Cancer Portfolio
by Zacks Equity Research
Pfizer (PFE) is set to buy Seagen (SGEN) in a $43 billion deal. Seagen's key products focus on cancer treatment.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK
by Kinjel Shah
FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.
Merck (MRK) Stock Moves -0.63%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $107.60, marking a -0.63% move from the previous day.
Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept
by Zacks Equity Research
Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.
Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl
by Zacks Equity Research
Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.
Zacks Value Investor Highlights: Merck, Coca-Cola, Coca-Cola Consolidated, American Express and Chevron
by Zacks Equity Research
Merck, Coca-Cola, Coca-Cola Consolidated, American Express and Chevron have been highlighted in this Value Investor article.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $106.88 in the latest trading session, marking a -0.12% move from the prior day.